Bank of New York Mellon’s Genocea Biosciences, Inc. GNCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-16,305
| Closed | -$20K | – | 4797 |
|
|
2022
Q1 | $20K | Hold |
16,305
| – | – | ﹤0.01% | 4616 |
|
|
2021
Q4 | $19K | Hold |
16,305
| – | – | ﹤0.01% | 4591 |
|
|
2021
Q3 | $31K | Hold |
16,305
| – | – | ﹤0.01% | 4484 |
|
|
2021
Q2 | $38K | Sell |
16,305
-2,535
| -13% | -$6.11K | ﹤0.01% | 4358 |
|
|
2021
Q1 | $51K | Sell |
18,840
-1,426
| -7% | -$4.22K | ﹤0.01% | 4257 |
|
|
2020
Q4 | $49K | Hold |
20,266
| – | – | ﹤0.01% | 4150 |
|
|
2020
Q3 | $46K | Hold |
20,266
| – | – | ﹤0.01% | 4029 |
|
|
2020
Q2 | $47K | Hold |
20,266
| – | – | ﹤0.01% | 3994 |
|
|
2020
Q1 | $35K | Buy |
+20,266
| New | +$40.9K | ﹤0.01% | 4012 |
|
|
2019
Q3 | – | Sell |
-17,054
| Closed | -$67K | – | 4314 |
|
|
2019
Q2 | $67K | Buy |
17,054
+14,412
| +545% | +$75.2K | ﹤0.01% | 4092 |
|
|
2019
Q1 | $12K | Sell |
2,642
-80
| -3% | -$396 | ﹤0.01% | 4190 |
|
|
2018
Q4 | $6K | Hold |
2,722
| – | – | ﹤0.01% | 4212 |
|
|
2018
Q3 | $17K | Hold |
2,722
| – | – | ﹤0.01% | 4218 |
|
|
2018
Q2 | $19K | Sell |
2,722
-21,674
| -89% | -$162K | ﹤0.01% | 4175 |
|
|
2018
Q1 | $205K | Buy |
24,396
+13,114
| +116% | +$109K | ﹤0.01% | 3924 |
|
|
2017
Q4 | $105K | Buy |
11,282
+576
| +5% | +$5.79K | ﹤0.01% | 4089 |
|
|
2017
Q3 | $125K | Buy |
10,706
+191
| +2% | +$7.25K | ﹤0.01% | 3971 |
|
|
2017
Q2 | $439K | Buy |
10,515
+9,001
| +595% | +$433K | ﹤0.01% | 3656 |
|
|
2017
Q1 | $74K | Hold |
1,514
| – | – | ﹤0.01% | 4085 |
|
|
2016
Q4 | $50K | Sell |
1,514
-160
| -10% | -$5.27K | ﹤0.01% | 4131 |
|
|
2016
Q3 | $69K | Sell |
1,674
-1,979
| -54% | -$77.6K | ﹤0.01% | 4091 |
|
|
2016
Q2 | $120K | Sell |
3,653
-4,890
| -57% | -$179K | ﹤0.01% | 4017 |
|
|
2016
Q1 | $529K | Sell |
8,543
-1,527
| -15% | -$48.5K | ﹤0.01% | 3416 |
|
|
2015
Q4 | $425K | Buy |
10,070
+930
| +10% | +$44.3K | ﹤0.01% | 3600 |
|
|
2015
Q3 | $500K | Buy |
9,140
+783
| +9% | +$77.6K | ﹤0.01% | 3585 |
|
|
2015
Q2 | $918K | Buy |
8,357
+5,510
| +194% | +$512K | ﹤0.01% | 3389 |
|
|
2015
Q1 | $270K | Buy |
2,847
+1,185
| +71% | +$83.6K | ﹤0.01% | 3817 |
|
|
2014
Q4 | $93K | Sell |
1,662
-35
| -2% | -$2.39K | ﹤0.01% | 4063 |
|
|
2014
Q3 | $123K | Hold |
1,697
| – | – | ﹤0.01% | 3998 |
|
|
2014
Q2 | $255K | Buy |
+1,697
| New | +$257K | ﹤0.01% | 3782 |
|
Other funds holding GNCA
Bank of New York Mellon's GNCA Position: Q2 2022 in Review
Bank of New York Mellon sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 16,305 shares — an estimated $20K sold.
Bank of New York Mellon first reported a position in GNCA in Q2 2014 and held it in 30 quarters. The position peaked at $918K in Q2 2015. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.
- Bank of New York Mellon reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
- Bank of New York Mellon sold 16,305 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $20K.
- Bank of New York Mellon first reported a position in Genocea Biosciences, Inc. in Q2 2014 and held it in 30 quarters.
- Bank of New York Mellon's Genocea Biosciences, Inc. position peaked at $918K in Q2 2015.
- 5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.
Based on Bank of New York Mellon's 13F filing for Q2 2022, filed 15 Aug 2022.